London/Mumbai: Novartis AG agreed to buy GlaxoSmithKline Plc's (GSK's) cancer-drug business for as much as $16 billion, form a consumer-health venture with GSK and sell its animal-health operation to Eli Lilly and Co.
... (PHG, PHIA.AE). Drug giants Novartis and GlaxoSmithKline unveiled a series of transactions worth more than $20 billion that fundamentally transform both companies, focusing Novartis's scope without significantly hitting its revenue and turning ...
The General election is just over 12 months away, and the latest YouGov poll shows Labour with a 7% lead over the Tories. It could be time for investors to position their portfolios in anticipation of a potential Labour victory.
Dallas, Texas, 04/21/2014 (ustrademedia) - GlaxoSmithKline plc (NYSE:GSK) is global healthcare conglomerate which engages in the invention and discovery, development, manufacture and marketing of pharmaceutical products.
GlaxoSmithKline plc (ADR) logo GlaxoSmithKline plc (ADR) (NYSE:GSK) was upgraded by investment analysts at Panmure Gordon from a �hold� rating to a �buy� rating in a note issued to investors on Tuesday, Analyst Ratings Network reports.
A diabetes drug approved last week for sale in the U.S. and Europe brings GlaxoSmithKline (GSK) into a new therapy field for the company, one that is both crowded and changing rapidly with the ageing of baby boomers and new directions in health care.
GlaxoSmithKline plc (ADR) (NYSE:GSK) last announced its earnings results on Wednesday, February 5th. The company reported $0.30 EPS for the quarter, meeting the Thomson Reuters consensus estimate of $0.30.